登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>LILRB4 >SCCHO-ATP087

CHO/Human LILRB4 Stable Cell Line Development Service

For research use only.
此产品为在研产品。如果您对此产品有兴趣,请直接联系我们。我们会根据您的需求相应地加速我们的研发进程,并为您进行产品预留。

描述(Description)

CHO/Human LILRB4 Stable Cell Line

应用说明(Application)

• Useful for cell-based LILRB4 binding assay

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Hygromycin (20 μg/mL)

培养基(Culture Medium)

F-12K + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

背景(Background)

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
LILRB4靶点信息
英文全称:Leukocyte immunoglobulin-like receptor subfamily B member 4
中文全称:免疫抑制受体LILRB4
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:6详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定